Apolipoprotein News and Research

RSS

Journal of Alzheimer's Disease highlights latest scientific studies of AD

A supplement to the Journal of Alzheimer's Disease on "Anesthetics and Alzheimer's Disease" provides the platform to bring the latest scientific studies to the AD research and clinical communities.

15 Nov 2010

New findings pave way to improve early detection of ovarian cancer

A drug in testing to treat atherosclerosis significantly inhibited growth of ovarian cancer in both human cell lines and mouse models, the first such report of a peptide being used to fight malignancies, according to a study by researchers at UCLA's Jonsson Comprehensive Cancer Center.

2 Nov 2010

New gene therapy product reduces plasma cholesterol levels

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans

25 Oct 2010

Injecting apoA-V protein may reduce high triglyceride levels: Research

Injecting a protein that helps break down triglycerides may someday help treat an inherited form of high triglycerides, according to a new study in Arteriosclerosis, Thrombosis, and Vascular Biology, an American Heart Association journal.

22 Oct 2010

Study: apoA-V may reduce high triglyceride levels, coronary artery disease

An exciting new study conducted by Children's Hospital Oakland Research Institute scientists identified that an injection of the protein apolipoprotein A-V may reduce high triglyceride levels in the blood and subsequently reduce coronary artery disease. Like cholesterol, elevated levels of triglyceride, a fat in the blood, is associated with the increased risk of heart disease—the number one cause of death in the United States.

22 Oct 2010

ApoE4 protein causes GABAergic interneuron loss, learning and memory deficits

Alzheimer's disease (AD) is an extremely complicated disease. Several proteins seem to be involved in its cause and progression. For example, the lipid-transport protein apolipoprotein E4 (apoE4) is the major genetic risk factor for AD, and apoE4 carriers account for 65% of all Alzheimer's cases, but exactly how apoE4 contributes to the disease is unclear.

14 Oct 2010

Low level of testosterone increases risk for Alzheimer's disease

Low levels of the male sex hormone, testosterone, in older men is associated with the onset of Alzheimer's disease, according to research by a team that includes a Saint Louis University scientist.

6 Oct 2010

Study shows blueberries may help fight atherosclerosis

Blueberries may help fight atherosclerosis, also known as hardening of the arteries, according to results of a preliminary U.S. Department of Agriculture funded study with laboratory mice. The research provides the first direct evidence that blueberries can help prevent harmful plaques or lesions, symptomatic of atherosclerosis, from increasing in size in arteries.

30 Sep 2010

Researchers find bariatric surgery reduces cardiovascular disease risk

Significant weight loss not only improves daily life of morbidly obese woman but also decreases the risk for cardiovascular disease (CVD). However, many people can not lose weight or can not maintain weight loss without help. Bariatric surgery is emerging as a valuable procedure to help morbidly obese individuals lose weight, as studies have shown; it can improve many health profiles and lower mortality. Now, researchers have found another positive impact of significant weight loss after bariatric surgery, it can significantly improve the lipoprotein profiles of women within a year following surgery.

17 Sep 2010

Gene network behind hardening of arteries, coronary heart disease identified

A gene network behind hardening of the arteries and coronary heart disease has been identified by a team of scientists from Australia, Europe and the United Kingdom. Their findings expose potential targets for the treatment of heart disease.

16 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

Research on trypanosomes can open way for African sleeping sickness drug development

Trypanosomes are parasites responsible for many human and animal diseases, primarily in tropical climates. One disease these parasites cause, African sleeping sickness, results from the bite of infected tsetse flies, putting over 60 million Africans at risk in 36 sub-Saharan countries. The recent 1998-2001 sleeping sickness epidemics in South Sudan, Angola, Democratic Republic of Congo and Uganda killed tens of thousands of people and resulted in over a half million infected individuals.

31 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Alnylam Pharmaceuticals reports significant progress in discovery of novel technologies for systemic delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology (MIT), The University of British Columbia (UBC), AlCana Technologies, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing research efforts regarding the discovery of novel technologies for the systemic delivery of RNAi therapeutics.

10 Aug 2010

Researchers use new biomarkers to study structure of protein deposits caused by Alzheimer's disease

Researchers at Mount Sinai School of Medicine have used a newly discovered class of biomarkers to investigate the possibility that the shape of brain protein deposits is different in people with Alzheimer's who have the highest-risk gene type than in those with the condition who have a neutral risk gene type. The study is being presented July 14 at the 2010 Alzheimer's Association International Conference on Alzheimer's Disease in Honolulu, Hawaii.

15 Jul 2010

Phytonutrient-based medical food and heart-healthy diet reduce CVD risk factors: Study

New research presented at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida on June 27, 2010 suggests that a medical food developed by Metagenics, Inc. called UltraMeal® PLUS 360° enhances the cardiovascular disease (CVD) risk-lowering benefits of a Mediterranean-style low-glycemic-load diet.

29 Jun 2010

Researchers suggest factors that predict pre-Alzheimer's condition

Mild cognitive impairment is often seen as a transition stage between the cognitive decline of normal aging and the more serious problems of Alzheimer's disease. But what leads to mild cognitive impairment?

29 Jun 2010

Resverlogix' RVX-208 increases plasma levels of Apolipoprotein A-I and HDL-cholesterol

Resverlogix is pleased to announce that it has collaborated with the Division of Cardiology at the Research Institute of the McGill University Health Centre (RI of the MUHC), to publish today in the Journal of American College of Cardiology (JACC), a report entitled 'RVX-208 A Small Molecule that Increases Apolipoprotein A-I and High Density Lipoprotein Cholesterol In Vitro and In Vivo'.

9 Jun 2010

Two variants of LPA gene associated with increased risk of coronary heart disease

Celera Corporation and its collaborators at the University of California at San Francisco today announced the publication of a paper confirming the association of an increased risk of coronary heart disease (CHD) and two variants of the LPA gene. The two LPA single nucleotide polymorphisms (SNPs) are Ile4399Met, a polymorphism in the protease-like domain of LPA, and rs10455872, a SNP located in a non-coding region of the LPA gene.